ACT Onco® + Report

PATIENT	
Identifier: 陳文琳	Patient ID: 10748773
Date of Birth: Jan 30, 1981	Gender: Female
Diagnosis: Hepatocellular carcinoma	
ORDERING PHYSICIAN	
Name: 姜乃榕醫師	Tel: 886-228712121
Facility: 臺北榮總	
Address: 臺北市北投區石牌路二段 201 號	
SPECIMEN		
Specimen ID: S2306992	Collection site: Liver	Type: FFPE tissue
Date received: Jun 19, 2023	Lab ID: AA-23-04025	D/ID: NA

ABOUT ACTOnco®+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) (≤ 15 nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

SUMMARY FOR ACTIONABLE VARIANTS

VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	**Resistant**	
Not detected			

VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
Not detected		

Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criterial for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

行動基因僅提供技術檢測服務及檢測報告，檢測結果之臨床解釋及相關醫療處置，請諮詢專業醫師。報告結果僅對此試驗件有效。
行動基因臨床分子醫學實驗室　台北市內湖區新湖二路345號3F
Email: service@actgenomics.com　T: +886-2-2795-3660　F: +886-2-2795-5016

AG4-QP4001-02(07)

page **1** of 16

ACT Onco® + Report

TESTING RESULTS

VARIANT(S) WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
AXIN1	W635*	63.6%

- Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr16	AXIN1, TSC2	Heterozygous deletion	1

- Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

- Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	1.9 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

Note:

- Variant(s) enlisted in the SNV table may currently exhibit no relevance to treatment response prediction. Please refer to INTERPRETATION for more biological information and/or potential clinical impacts of the variants.
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 72% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is < 30%.

ACT Onco® + Report

THERAPEUTIC IMPLICATIONS

TARGETED THERAPIES

Not Applicable.

IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

- Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

行動基因僅提供技術檢測服務及檢測報告，檢測結果之臨床解釋及相關醫療處置，請諮詢專業醫師。報告結果僅對此試驗件有效。
行動基因臨床分子醫學實驗室　台北市內湖區新湖二路345號3F
Email: service@actgenomics.com　　T: +886-2-2795-3660　　F: +886-2-2795-5016

AG4-QP4001-02(07)

page 3 of 16

ACT Onco® + Report

VARIANT INTERPRETATION

AXIN1 W635*, Heterozygous deletion

Biological Impact

AXIN1 gene encodes a scaffold protein that is a component of the beta-catenin destruction complex. In the complex, AXIN1 provide scaffolding for the APC, GSK-3 beta and beta-catenin, which enables the degradation of beta-catenin in the absence of WNT ligand binding and negatively regulates WNT signaling pathway[1][2]. Somatic mutations and deletions of AXIN1 have been reported in hepatocellular carcinoma[3], medulloblastoma[4][5], gastrointestinal cancer[6], and colorectal cancer[7].

W635* mutation results in a premature truncation of the AXIN1 protein at amino acid 635 (UniProtKB). This mutation is predicted to lead to a loss of AXIN1 function, despite not having characterized in the literature. Loss of the second wild-type allele resulted in the biallelic inactivation of the gene.

Therapeutic and prognostic relevance

A retrospective study (n = 124) has demonstrated that reduced AXIN expression in tumor specimen was associated with poor survival in patients with esophageal squamous cell carcinoma (ESCC)[8].

TSC2 Heterozygous deletion

Biological Impact

The tuberous sclerosis complex 2 (TSC2) gene encodes a protein called tuberin, which interact with a protein called hamartin (encoded by the TSC1 gene). This hamartin-tuberin tumor suppressor complex plays a critical role in growth control as a negative regulator of the mammalian target of rapamycin (mTOR) pathway[9][10]. Mutations in TSC1/TSC2 tumor suppressor genes that result in inactivation of the complex are commonly found in patients with tuberous sclerosis complex[11][12][13], while the loss of heterozygosity (LOH) in TSC1/TSC2 has been identified in head and neck squamous cell carcinoma (HNSCC)[14] and endometrial cancer[15]. TSC2 deletion, splicing-mutant, and inactivating mutations such as A1141T, G305V, S1514X, and R1032X, has been identified in TSC2-null hepatocellular carcinoma (HCC) cell lines, patient-derived xenograft, and primary tumors. Mutations in the TSC1 and TSC2 genes cause the autosomal dominant genetic disorder tuberous sclerosis complex (TSC)[16].

Therapeutic and prognostic relevance

Everolimus is FDA-approved for treating Tuberous Sclerosis Complex (TSC)-associated renal angiomyolipoma and Tuberous Sclerosis Complex (TSC)-associated subependymal giant cell astrocytoma (SEGA).

TSC1/2 mutation/loss has been selected as an inclusion criteria for the trials examining temsirolimus efficacy in mutiple cancer types (NCT02693535, NCT03297606).

TSC1/TSC2 genomic alterations activate the mTOR signaling pathway and confer sensitivity to mTOR inhibitors, including everolimus, sirolimus, and temsirolimus. Everolimus is effective in multiple cancers, such as bladder tumors, gastric, sarcoma, thyroid cancer, and HNSCC[17][18]. Sirolimus is effective in treating malignant uterine PEComa with TSC1/TSC2 mutations/deletions[19][20][21], while temsirolimus is effective in those with hyperactivated mTOR pathway[22]. In advanced endometrial cancer, TSC1, and TSC2 mutations may predict clinical benefits from temsirolimus with or without megestrol acetate and tamoxifen[23].

ACT Onco® + Report

US FDA-APPROVED DRUG(S)

Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

- FDA Approval Summary of Everolimus (AFINITOR)

RADIANT-4[24] NCT01524783	**Lung or gastrointestinal neuroendocrine tumor** (Approved on 2016/02/26)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
BOLERO-2[25] NCT00863655	**Breast cancer** (Approved on 2012/07/20)
	ER+/HER2-
	Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
EXIST-2 NCT00790400	**Tuberous sclerosis complex (tsc)-associated renal angiomyolipoma** (Approved on 2012/04/26)
	-
	Everolimus vs. Placebo [ORR(%): 41.8 vs. 0]
RADIANT-3[26] NCT00510068	**Pancreatic neuroendocrine tumor** (Approved on 2011/05/05)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
EXIST-1[27] NCT00789828	**Subependymal giant cell astrocytoma** (Approved on 2010/10/29)
	-
	Everolimus vs. Placebo [ORR(%): 35.0]
RECORD-1[28] NCT00410124	**Renal cell carcinoma** (Approved on 2009/05/30)
	-
	Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

Temsirolimus (TORISEL)

Temsirolimus is a soluble ester of sirolimus (rapamycin, brand-name drug Rapamune) and functions as an inhibitor of mammalian target of rapamycin complex (mTORC). The inhibitory molecular mechanism is similar to Everolimus. Temsirolimus is developed by Wyeth Pharmaceuticals and marketed by Pfizer under the trade name TORISEL.

- FDA Approval Summary of Temsirolimus (TORISEL)

[29] NCT00065468	**Renal cell carcinoma** (Approved on 2007/05/30)
	-
	Temsirolimus vs. Ifn-α [OS(M): 10.9 vs. 7.3]

D=day; W=week; M=month

行動基因僅提供技術檢測服務及檢測報告，檢測結果之臨床解釋及相關醫療處置，請諮詢專業醫師。報告結果僅對此試驗件有效。
行動基因臨床分子醫學實驗室　台北市內湖區新湖二路345號3F
Email: service@actgenomics.com　　T: +886-2-2795-3660　　F: +886-2-2795-5016

AG4-QP4001-02(07)

page 5 of 16

ACT Onco® + Report

ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit https://clinicaltrials.gov to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACT Onco® + Report

SUPPLEMENTARY INFORMATION OF TESTING RESULTS
DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
AXIN1	W635*	7	c.1904G>A	NM_003502	COSM6914520	63.6%	621

- Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.

AA-23-04025

○ Observed CN ≥ 3 but < 4
● Observed CN ≥ 4
● Observed CN < 2

ACT Onco® + Report

OTHER DETECTED VARIANTS

| Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ADH1C	R364H	8	c.1091G>A	NM_000669	-	21.8%	193
ARID1A	V1982I	20	c.5944G>A	NM_006015	COSM1580528	82.6%	494
CCND3	S259T	5	c.775T>A	NM_001760	-	36.4%	3188
CIC	Splice region	-	c.4460-8A>G	NM_015125	-	50.0%	166
HIST1H1C	A123T	1	c.367G>A	NM_005319	COSM2857683	62.9%	491
HIST1H1C	V20E	1	c.59T>A	NM_005319	-	59.9%	1191
PAX8	S325F	9	c.974C>T	NM_003466	-	52.8%	494
SYNE1	T2303M	47	c.6908C>T	NM_182961	COSM6902235	84.0%	338
TGFBR2	R193W	4	c.577C>T	NM_003242	-	87.1%	1292
USH2A	N2356K	37	c.7068T>G	NM_206933	-	30.2%	2101
WT1	Q209R	1	c.626A>G	NM_024426	-	66.2%	684

Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

行動基因僅提供技術檢測服務及檢測報告，檢測結果之臨床解釋及相關醫療處置，請諮詢專業醫師。報告結果僅對此試驗件有效。
行動基因臨床分子醫學實驗室　台北市內湖區新湖二路345號3F
Email: service@actgenomics.com　T: +886-2-2795-3660　F: +886-2-2795-5016

AG4-QP4001-02(07)

page 8 of 16

ACT Onco® + Report

TEST DETAILS

SPECIMEN RECEIVED AND PATHOLOGY REVIEW

- Collection date: Apr 21, 2023
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S2306992
- Collection site: Liver
- Examined by: Dr. Yun-An Chen
    1. The percentage of viable tumor cells in total cells in the whole slide (%): 60%
    2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 60%
    3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
    4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
    5. Additional comment: NA
- Manual macrodissection: Not performed
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

RUN QC

- Panel: ACTOnco®+

DNA test

- Mean Depth: 904x
- Target Base Coverage at 100x: 95%

RNA test

- Average unique RNA Start Sites per control GSP2: 117

ACT Onco®+ Report

LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

NEXT-GENERATION SEQUENCING (NGS) METHODS

DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage ≥ 20, allele frequency ≥ 5% and actionable variants with allele frequency ≥ 2% were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at 100x ≥ 85% with a mean coverage ≥ 500x.

Variants reported in Genome Aggregation database with > 1% minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:
Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is < 30%.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

行動基因僅提供技術檢測服務及檢測報告，檢測結果之臨床解釋及相關醫療處置，請諮詢專業醫師。報告結果僅對此試驗件有效。
行動基因臨床分子醫學實驗室　台北市內湖區新湖二路345號3F
Email: service@actgenomics.com　　T: +886-2-2795-3660　　F: +886-2-2795-5016

AG4-QP4001-02(07)　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　page **10** of **16**

ACT Onco® + Report

RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be ≥ 10.

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2 ≥ 3; (2) Number of supporting reads spanning the fusion junction ≥ 5; (3) Percentage of supporting reads spanning the fusion junction ≥ 10%; (4) Fusions annotated in Quiver Gene Fusion Database.

DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

Variant Analysis:

醫檢師黃靖婷 博士
Ching-Ting Huang Ph.D.
檢字第 016511 號

Sign Off

解剖病理專科醫師王業翰
Yeh-Han Wang M.D.
病解字第 000545 號

ACT Onco® + Report

GENE LIST

SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTK	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBKB	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLCO1B1*
SLCO1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOCS1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

*Analysis of copy number alterations NOT available.

FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1

行動基因僅提供技術檢測服務及檢測報告，檢測結果之臨床解釋及相關醫療處置，請諮詢專業醫師。報告結果僅對此試驗件有效。
行動基因臨床分子醫學實驗室　台北市內湖區新湖二路345號3F
Email: service@actgenomics.com　T: +886-2-2795-3660　F: +886-2-2795-5016

AG4-QP4001-02(07)

page 12 of 16

ACT Onco® + Report

APPENDIX

POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Gene	Therapies	Possible effect
TSC2	Everolimus, Temsirolimus	**sensitive**

SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS

1: Everolimus, Temsirolimus

ACT Onco® + Report

DISCLAIMER

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

ACT Onco® + Report

REFERENCE

1.   PMID: 9734785; 1998, Genes Cells;3(6):395-403
     Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level.

2.   PMID: 23169527; 2013, Cold Spring Harb Perspect Biol;5(1):a007898
     The β-catenin destruction complex.

3.   PMID: 12101426; 2002, Oncogene;21(31):4863-71
     Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.

4.   PMID: 12555076; 2003, Oncogene;22(4):632-6
     AXIN1 mutations but not deletions in cerebellar medulloblastomas.

5.   PMID: 11585731; 2001, Cancer Res;61(19):7039-43
     Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas.

6.   PMID: 25236910; 2014, Cancer Lett;355(1):1-8
     AXIN1 and AXIN2 variants in gastrointestinal cancers.

7.   PMID: 14566817; 2003, Int J Cancer;107(5):696-9
     Detection of point mutations of the Axin1 gene in colorectal cancers.

8.   PMID: 19582507; 2009, Ann Surg Oncol;16(9):2486-93
     Reduced axin protein expression is associated with a poor prognosis in patients with squamous cell carcinoma of esophagus.

9.   PMID: 21157483; 2011, Nat Rev Mol Cell Biol;12(1):21-35
     mTOR: from growth signal integration to cancer, diabetes and ageing.

10. PMID: 12271141; 2002, Proc Natl Acad Sci U S A;99(21):13571-6
     Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

11. PMID: 9242607; 1997, Science;277(5327):805-8
     Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.

12. PMID: 8269512; 1993, Cell;75(7):1305-15
     Identification and characterization of the tuberous sclerosis gene on chromosome 16.

13. PMID: 1303246; 1992, Nat Genet;2(1):37-41
     Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease.

14. PMID: 18538015; 2008, BMC Cancer;8():163
     Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.

15. PMID: 28339086; 2017, Int J Oncol;50(5):1778-1784
     Identification of novel mutations in endometrial cancer patients by whole-exome sequencing.

16. PMID: 17005952; 2006, N Engl J Med;355(13):1345-56
     The tuberous sclerosis complex.

17. PMID: 22923433; 2012, Science;338(6104):221
     Genome sequencing identifies a basis for everolimus sensitivity.

18. PMID: 26859683; 2016, Oncotarget;7(9):10547-56
     Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

19. PMID: 20048174; 2010, J Clin Oncol;28(5):835-40
     Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of

行動基因僅提供技術檢測服務及檢測報告，檢測結果之臨床解釋及相關醫療處置，請諮詢專業醫師。報告結果僅對此試驗件有效。
行動基因臨床分子醫學實驗室　台北市內湖區新湖二路345號3F
Email: service@actgenomics.com　　T: +886-2-2795-3660　　F: +886-2-2795-5016

AG4-QP4001-02(07)

page **15** of **16**

ACT Onco® + Report

mTORC1 in tumors.

20. PMID: 34637337; 2021, J Clin Oncol;39(33):3660-3670
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors.

21. PMID: 34442003; 2021, J Clin Med;10(16):
Efficacy of Sirolimus Treatment in PEComa-10 Years of Practice Perspective.

22. PMID: 20215136; 2010, Ann Oncol;21(5):1135-7
Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.

23. PMID: 27016228; 2016, Gynecol Oncol;141(1):43-8
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

24. PMID: 26703889; 2016, Lancet;387(10022):968-977
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

25. PMID: 22149876; 2012, N Engl J Med;366(6):520-9
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

26. PMID: 21306238; 2011, N Engl J Med;364(6):514-23
Everolimus for advanced pancreatic neuroendocrine tumors.

27. PMID: 23158522; 2013, Lancet;381(9861):125-32
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

28. PMID: 18653228; 2008, Lancet;372(9637):449-56
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

29. PMID: 17538086; 2007, N Engl J Med;356(22):2271-81
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

行動基因僅提供技術檢測服務及檢測報告，檢測結果之臨床解釋及相關醫療處置，請諮詢專業醫師。報告結果僅對此試驗件有效。
行動基因臨床分子醫學實驗室　台北市內湖區新湖二路345號3F
Email: service@actgenomics.com　T: +886-2-2795-3660　F: +886-2-2795-5016

AG4-QP4001-02(07)

page **16** of **16**